My Profile

Search abstracts

Lewis Sheiner


2019
Stockholm, Sweden



2018
Montreux, Switzerland

2017
Budapest, Hungary

2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
København, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland



Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

Reference:
PAGE 8 (1999) Abstr 154 [www.page-meeting.org/?abstract=154]


poster


Comparison of Three Methods to Analyse the Population Pharmacokinetics of High-Dose Carboplatin in Patients with Testicular Carcinoma

Georg Hempel1,2, Christiane Eickhoff3, Charlotte Kloft3, Ulrich Jaehde4

1 Universitäts-Kinderklinik, Abt.Hämatologie/Onkologie, Münster, Germany; 2 Institut für Pharmazeutische Chemie, Universität Münster, Germany; 3 Institut für Pharmazie, -Klinische Pharmazie-, Freie Universität Berlin, Germany; 4 Pharmazeutisches Institut, Universität Bonn, Germany

Introduction: Carboplatin is a widely used cytotoxic agent showing activity against several solid tumours. To reduce the variability in the individual exposure, dose adjustment based on renal function (e.g. creatinine clearance CrCl) has been suggested. To investigate the influence of several covariables for the kinetics of ultrafilterable carboplatin, we analysed a data set using three different approaches.

Methods: Blood samples from 29 patients receiving 400 to 500 mg/m2 carboplatin as a 1h infusion on three consecutive days were collected and analysed for ultrafilterable platinum. On average, 14 samples per patient were available. In addition, the following covariables were assessed: age, weight, height, body surface area (BSA) and CrCl (estimated by the Cockroft-Gault formula). An open two-compartment model was used. Three different methods were applied to analyse the data: standard two stage (MicropharmÒ ), the EM-algorithm using PPharm and NONMEM.

Results: The population pharmacokinetic parameters found are as follows:

 

STS

 

NONMEM

 

PPharm

   
 

Mean

SD

Mean

SD

Mean

SD

CL [l/h]

6.78

1.8

7.62

1.8

6.63

3.2

Vcentral[l]

21.3

3.6

21.4

2.9

19.9

1.6

t1/2 alpha [h]

2.00

0.50

1.93

0.48

1.99

0.42

t1/2 beta [h]

35.4

6.5

34.3

8.5

35.2

6.4

SD: standard deviation

For carboplatin clearance, CrCl and height were identified as cofactors by the PPharm analysis. In contrast, in the NONMEM analysis besides CrCl BSA showed the highest correlation to carboplatin clearance.

Conclusion: The three methods used provide similar population parameters whereas different results were obtained in the covariate analysis. As reported earlier, by implementing CrCl in the model the prediction of the individual clearance can be significantly improved. Currently, the applicability of the NONMEM model is further investigated in a data set of 69 patients receiving carboplatin as a 1, 24 or 96 h infusions.